Neuracle NEO system: full technical specifications — Tsinghua-developed EEG decoding + pneumatic glove for SCI
Summary
Technical details revealed for the Neuracle NEO system, the world's first commercially approved invasive BCI: the NEO consists of implanted EEG electrodes positioned on the brain's outer membrane (epidural), a coin-sized wireless processor, a brain signal decoding algorithm developed at Tsinghua University, a pneumatic robotic glove controlled by decoded neural signals, clinical management software, and medical testing software. The system is designed specifically for cervical SCI patients who retain some upper arm movement, using fewer channels and epidural (not subdural) positioning compared to deeper competitors. Neuracle simultaneously announced preparation for an IPO on Shanghai's Star Market.
Why it matters
The NEO's technical approach — epidural electrodes with fewer channels, not penetrating to subdural or cortical levels — reflects a deliberate strategy to minimize surgical risk to achieve regulatory approval first, even if this limits bandwidth versus deeper competing systems. China's first-mover commercial BCI advantage rests on this deliberate clinical risk calibration.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial